Clinical trial
Radiotherapy With Concurrent Cetuximab vs. Carboplatin and Paclitaxel in Patients With Stage III-IVB Head and Neck Cancer With a Contraindication to Cisplatin: A Pragmatic Phase III Randomized Trial
NCT07441681 is registered in ClinicalTrials.gov with NRG Oncology as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Radiotherapy With Concurrent Cetuximab vs. Carboplatin and Paclitaxel in Patients With Stage III-IVB Head and Neck Cancer With a Contraindication to Cisplatin: A Pragmatic Phase III Randomized Trial
- Lead sponsor
- NRG Oncology
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- July 31, 2026
- Completion date
- November 30, 2040
- Enrollment
- 454 (estimated)
- Sites
- 63
Conditions
As the registry lists them; a condition with its own page is linked.
clinical stage i hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8, clinical stage ii hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8, clinical stage iii hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8, head and neck squamous cell carcinoma, stage iii hypopharyngeal carcinoma ajcc v8, stage iii laryngeal cancer ajcc v8, stage iii lip and oral cavity cancer ajcc v8, stage iii oropharyngeal (p16-negative) carcinoma ajcc v8, stage iva hypopharyngeal carcinoma ajcc v8, stage iva laryngeal cancer ajcc v8, stage iva lip and oral cavity cancer ajcc v8, stage iva oropharyngeal (p16-negative) carcinoma ajcc v8, stage ivb hypopharyngeal carcinoma ajcc v8, stage ivb laryngeal cancer ajcc v8, stage ivb lip and oral cavity cancer ajcc v8, stage ivb oropharyngeal (p16-negative) carcinoma ajcc v8